Investigators reported a novel derivative of lonidamine, namely HYL001, which selectively and potently inhibited CSCs by targeting mitochondria.
[Pharmacological Research]
A Novel Lonidamine Derivative Targeting Mitochondria to Eliminate Cancer Stem Cells by Blocking Glutamine Metabolism
